Slingshot members are tracking this event:
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|MRK||Community voting in process|
Slingshot Insights Explained
Mar 07, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Sbla, Pembrolizumab, Keytruda, Pd-l1, Chemotherapy, Cancer Cells, Keynote-010